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ABSTRACT
There is growing evidence that supplementation with carnosine, or its rate-limiting precursor β-alanine, can ameliorate aspects of metabolic
dysregulation that occur in diabetes and its related conditions. The purpose of this systematic review and meta-analysis was to evaluate the effect of
carnosine or β-alanine supplementation on markers of glycemic control and insulin resistance in humans and animals. We performed a systematic
search of 6 electronic databases up to 31 December 2020. Primary outcomes were changes in 1) fasting glucose, 2) glycated hemoglobin (HbA1c),
and 3) 2-h glucose following a glucose-tolerance test. A set of additional outcomes included fasting insulin and homeostatic model assessment of
β-cell function (HOMA-β) and insulin resistance (HOMA-IR). We assessed risk of bias using the Cochrane risk of bias (RoB) 2.0 (human studies) and the
Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) RoB (animal studies) tools; and used the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE) approach to assess certainty. We used Bayesian hierarchical random-effects models, with
informative priors for human data and noninformative priors for animal data. Inferences were made on posterior samples generated by Hamiltonian
Markov Chain Monte Carlo using 90% credible intervals (90% CrI) and calculated probabilities. Twenty studies (n = 4 human, n = 16 rodent) were
included, providing data for 2 primary outcomes (fasting glucose and HbA1c) and 3 additional outcomes (fasting insulin, HOMA-β , and HOMA-IR).
The model provides evidence that supplementation decreases fasting glucose [humans: mean difference (MD)0.5 = –0.95 mmol · L–1 (90% CrI: –2.1,
0.08); rodent: MD0.5 = –2.26 mmol · L–1 (90% CrI: –4.03, –0.44)], HbA1c [humans: MD0.5 = –0.91% (90% CrI: –1.46, –0.39); rodents: MD0.5 = –1.05%
(90% CrI: –1.64, –0.52)], HOMA-IR [humans: standardized mean difference (SMD)0.5 = –0.41 (90% CrI: –0.82, –0.07); rodents: SMD0.5 = –0.63 (90% CrI:
–1.98, 0.65)], and fasting insulin [humans: SMD0.5 = –0.41 (90% CrI: –0.77, –0.07)]. GRADE assessment showed our certainty in the effect estimate
of each outcome to be moderate (human outcomes) or very low (rodent outcomes). Supplementation with carnosine or β-alanine may reduce
fasting glucose, HbA1c, and HOMA-IR in humans and rodents, and fasting insulin in humans; both compounds show potential as therapeutics to
improve glycemic control and insulin resistance. This review was registered at PROSPERO as CRD42020191588. Adv Nutr 2021;00:1–16.
Statement of Significance: This study includes all available human and animal data to provide the most comprehensive assessment to date
of the effects of carnosine and β-alanine supplementation on glycemic control and insulin resistance.
Keywords: endocrinology, histidine, metabolic health, metabolism, nutrition, obesity
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Introduction
Diabetes is a major public health problem; worldwide esti-
mates show that 463 million people were living with diabetes
in 2019—equivalent to 9.3% of the global population (1).
Type 2 diabetes accounts for >90% of these cases, with the
remaining made up of type 1 diabetes, gestational diabetes,
and rarer types of diabetes (e.g., maturity-onset diabetes of
the young). A hallmark of type 2 diabetes is poor glycemic
control and insulin resistance (2), which present earlier in
life as impaired fasting glucose or impaired glucose tolerance
(also known as prediabetes). This represents a high-risk state
that requires intervention, as a 45-y-old with prediabetes has
a 74% lifetime risk of progression to type 2 diabetes (3). While
lifestyle modifications are central to risk reduction, they can
be challenging to implement, and long-term adherence limits
their effectiveness (4). It is therefore essential to develop low-
cost, novel therapies to improve glycemic control and help
prevent or delay disease progression.
The multifunctional dipeptide carnosine is an emerging
therapeutic that has the potential to contribute to the
treatment or management of various chronic diseases (5).
Carnosine is a member of the histidine-containing dipeptide
(HCD) family and exists naturally in high concentrations
in skeletal muscle, with smaller amounts in other excitable
tissues (6–9). Dietary sources include meat, poultry, fish, and
prawns (10); but the most efficient way to increase tissue
stores is by supplementing with carnosine or its rate-limiting
precursor β-alanine (11). Work from our research group
shows that treatment with carnosine recovers glucolipotoxic
inhibition of insulin-stimulated glucose uptake in skeletal
muscle cells and decreases highly toxic lipid peroxidation
products in pancreatic β-cells, leading to an increase in
insulin secretion (12). Further evidence supports the role
of carnosine in nonenzymatic detoxification of reactive
aldehydes (13, 14), an effect that β-alanine supplementation
potentiates in humans (15, 16). This has important clinical
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implications, as reactive aldehydes have been implicated
in the etiology of diabetes (17). Collectively, this suggests
that carnosine may be able to ameliorate aspects of the
metabolic dysregulation that occurs in diabetes and its
related conditions.
There is growing evidence from rodent studies that carno-
sine supplementation can prevent or delay the development
of type 2 diabetes (18, 19). Initial human trials also show
promise (20, 21), but there is currently no consensus on
whether carnosine or β-alanine can be used to treat or
manage diabetes. A recent meta-analysis of human studies
sought to address this knowledge gap and concluded that
supplementation with HCDs improved waist circumference,
fasting glucose, and glycated hemoglobin (HbA1c) (22). The
review, however, had several methodological shortcomings
[for a commentary, see (23)], which included combining
effects from studies using multi-ingredient supplements with
those supplementing carnosine or β-alanine alone. They also
included studies supplementing histidine in isolation, which
is not a member of the HCD family, and is not rate limiting
for carnosine synthesis in humans—at least under standard
dietary conditions (24–27). This approach cannot explain
whether the beneficial effects are due to carnosine, β-alanine,
HCDs, or another supplement ingredient. Another meta-
analysis on the topic also had methodological issues (28),
which included an incomplete and inconsistent risk of bias
assessment and the inclusion of the same study sample as 2
separate studies. It is also important to consider outcomes
from animal studies, which can provide mechanistic insight
and inform future human trials. Therefore, the purpose of
this systematic review and meta-analysis was to evaluate the
effect of carnosine or β-alanine supplementation on markers
of glycemic control and insulin resistance in humans and
animals.
Methods
The methods for this study were published in full as
a protocol paper (29) and preregistered on PROSPERO
(CRD42020191588). Our reporting follows the updated 2020
Preferred Reporting Items for Systematic review and Meta-
Analysis (PRISMA) guidelines (30).
Eligibility criteria
Table 1 outlines the eligibility criteria. The primary outcomes
were changes in fasting glucose (includes plasma, serum, and
blood glucose values), HbA1c, and 2-h glucose following a
glucose-tolerance test (GTT). These outcomes represent the
3 clinical markers used in the diagnosis of type 1 diabetes,
type 2 diabetes, prediabetes, and gestational diabetes (31,
32). A set of additional outcomes included changes in other
markers of glycemic control and insulin resistance (Table 1).
There were no restrictions on the timing or duration of
supplementation, or on the study setting. We included
English and non–English-language sources with the latter
translated into English using freely available online tools (i.e.,
Google Translate).
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TABLE 1 Overview of PICOS eligibility criteria1
Criteria
Participants Humans with type 1 diabetes, type 2 diabetes, prediabetes, gestational diabetes, impaired fasting glucose, or impaired
glucose tolerance [according to WHO guidelines (31, 32)], or with overweight/obesity (BMI ≥ 25 kg/m2) where the relevant
outcomes were collected and reported
Animal studies using a diabetes-related disease model (see human criteria), or overweight/obese animals where the relevant
outcomes were reported
No restrictions were applied on age or comorbidities, or on the methods used to induce disease in animal studies
Intervention Supplementation with carnosine or β-alanine. We excluded studies that used a multi-ingredient supplement intervention
Human studies included oral administration only, whereas animal studies also included administration by other means (e.g.,
intraperitoneal or intravenous injection)
Comparator Comparisons for human studies were between placebo and the experimental intervention
Comparisons for animal studies were between placebo or control (no intervention) and the experimental intervention
We excluded studies without a control or placebo group
Outcomes Outcomes relating to glycemic control and insulin resistance: fasting glucose, HbA1c, 2-h glucose following a GTT, fasting
insulin, C-peptide, homeostatic model assessment (HOMA) parameters (e.g., HOMA-IR, HOMA-β , HOMA-S)
Study designs Studies were limited to nonrandomized and RCTs, including cluster RCTs. We excluded cohort studies, cross-sectional studies,
case series, case reports, commentary, and review articles
1GGT, glucose-tolerance test; HbA1c, glycated hemoglobin; HOMA-β , homeostatic model assessment of β-cell function; HOMA-IR, homeostatic model assessment of insulin
resistance; HOMA-S, homeostatic model assessment of insulin sensitivity; PICOS, Participant, Intervention, Comparator, Outcomes, Study designs; RCT, randomized controlled trial.
Information sources
We searched 6 electronic databases for potentially eligible
studies—PubMed, Scopus, Web of Science, Cochrane Cen-
tral Register of Controlled Trials (CENTRAL), Cumulative
Index to Nursing and Allied Health Literature (CINAHL),
and ProQuest—from the earliest record in each database up
to 31 December 2020. This was supplemented by searching
for trial protocols, reference lists and citation tracking of
included studies, and relevant reviews. The authors also
searched their personal files to identify any additional
relevant material.
Search strategy and selection process
Search strategies were developed using key text words and
medical subject headings (MeSH) related to the population,
intervention, and outcomes. An academic librarian, not oth-
erwise associated with the project, reviewed all searches using
the Peer Review of Electronic Search Strategies (PRESS)
checklist (33). The full search strategy for each database and
the completed PRESS report are available in the Supplemen-
tal Methods. Two reviewers independently completed the
initial searches (JJM and KJE-S), data extraction (JJM and
ED), and assessment of risk of bias (JJM and ED); and 3
reviewers independently completed full-text screening (JJM,
LS, and GGA). Disagreements for searches, data extraction,
and risk of bias were referred to a third reviewer (CS) who
provided a recommendation.
Titles and abstracts of articles from the initial searches
were imported into a systematic review management plat-
form (Covidence; Veritas Health Innovation Ltd.); duplicates
were removed and remaining articles screened for poten-
tial eligibility. We obtained full texts for all articles that
appeared to meet the inclusion criteria or where there was
any uncertainty; multiple reports of the same study were
handled by including the article that provided the most
relevant outcome data. Reviewers used the reference manager
functions to highlight eligibility criteria and add comments
on each article to cross-reference decisions in the event
of a disagreement. We contacted study authors to resolve
issues regarding eligibility—for example, to clarify methods
or obtain necessary data (maximum of 3 e-mail attempts).
Reviewers were not blinded to journal titles or the study
authors.
Data-collection process and items
We extracted data using a standardized spreadsheet based
upon the Cochrane data collection form for intervention
reviews (34). Data items included the following: 1) study
characteristics (location, setting, study design, size, duration,
funding sources, and study aim), 2) human participant
characteristics (age, height, sex, body mass, BMI, body fat %,
type and duration of condition, activity and exercise levels,
and dietary information), 3) animal characteristics (age, body
mass, source, species, strain, sex, genetic modification status,
type and duration of condition, method used to induce dis-
ease, and housing conditions), 4) intervention characteristics
(name, type of control used, dosage, frequency, duration,
route of administration), 5) outcome characteristics (type of
measure; sample sizes; baseline, interim, and postinterven-
tion measures of central tendency and dispersion; adherence
to the intervention; dropouts; number and nature of side
effects; and assessment of blinding to the intervention),
and 6) information relevant to risk of bias and certainty
assessment. We converted glucose values to millimoles per
liter using a standard equation [mmol · L–1 = mg · dL–1 ×
0.0555; (35)]. We converted all supplement doses to relative
cumulative intake [mg · kg body weight (bw)–1]. Some
animal studies reported the treatment dose as grams per liter
dissolved in drinking water, which we multiplied by reported
or normative drinking volumes, before converting to an
estimate of relative cumulate intake. Where necessary, we
extracted measures of central tendency and dispersion from
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figures using WebPlotDigitizer version 3.10 (https://apps.
automeris.io/wpd/) or contacted study authors for additional
data (maximum of 3 e-mail attempts). We converted SE to SD
using a standard equation (SD = SE × √n).
Risk of bias assessment
Study risk of bias.
We assessed risk of bias in human studies using the
Cochrane risk of bias 2.0 tool (RoB 2) per protocol for
parallel-group randomized trials (36), and in animal studies
using the Systematic Review Centre for Laboratory Animal
Experimentation (SYRCLE) tool (37). Reviewers assessed
each study item as either “high risk,” “low risk,” “some
concerns” (RoB 2), or “unclear risk” (SYRCLE) of bias. For
human studies, we performed a summary judgment for
overall risk of bias based upon RoB 2 recommendations.
Reporting bias.
For human studies, we screened clinical trial registers to
compare outcomes reported in the protocol with each
published report. For animal studies, or where there was
no preregistration or protocol, we compared the outcomes
reported in the methods with the results section of each study.
Small study bias, including publication bias, was explored
by visually inspecting funnel plots and, where substantive
asymmetry was present, conducting a multilevel extension of
Egger’s regression test (38).
Effect measures
We extracted and analyzed all outcomes as continuous
measures. Mean difference (MD) effect sizes (not standard-
ized) were calculated for the primary outcomes: modeling
outcomes on the same absolute scale as the original measure-
ment provides more clinically interpretable results. We also
identified minimal important difference thresholds (fasting
glucose: 1 mmol · L–1 reduction; HbA1c: 0.5% reduction)
(39) and calculated the probability that the pooled effect
size met or exceeded threshold values (see Data synthesis
section). For additional outcomes, MD effect size estimates
were standardized (SMD) using reported SDs to account
for differences in measurement scales. We used standard
threshold values of 0.2, 0.5, and 0.8 to describe effect size
estimates as small, medium, and large (40), with values
between 0 and 0.2 described as trivial. Data collected from
human studies included both baseline and postintervention
values and effect sizes were calculated with both sets of
information (41), whereas effect sizes were calculated from
postintervention values only in animal studies (42).
Data synthesis
Meta-analyses were conducted within a Bayesian framework,
providing a flexible modeling approach to account for uncer-
tainty in model parameters and underlying structures within
the data. Bayesian models enable intuitive interpretation of
results through reporting subjective probabilities rather than
null hypothesis tests or frequentist confidence intervals (43).
We planned to conduct 3-level Bayesian hierarchical models
with noninformative priors for the between-study variance
parameters and adhered to this for analyses of animal data.
Due to limitations in the number of human studies and
effect sizes, a deviation from the original protocol (29)
was required. Instead, standard (2-level) Bayesian random-
effects models were conducted, and an informative log-t
distribution used as a prior for the between-study hetero-
geneity variance using a predictive distribution provided
for biological markers in pharmacologic versus placebo or
control studies (44). Informative priors were used in the
human data to estimate the within-study variances and
account for unknown correlations between baseline and
postintervention values. This was achieved by assuming a
uniform prior for each within-study variance based upon
a correlation ranging from 0.5 to 0.9. Inferences from all
analyses were performed on posterior samples generated by
Hamiltonian Markov chain Monte Carlo simulations, and
through use of the median value (0.5-quantile) and 90%
credible intervals (90% CrI) and calculated probabilities.
Sensitivity and subgroup analyses were performed to
examine the robustness of the main model results. Pre-
planned analyses included removing studies at high risk of
bias, as well as meta-regressions to explore the effect of
type of supplementation (carnosine or β-alanine), duration
of supplementation, and the disease type. Following data
extraction, additional sensitivity analyses were performed for
clear outliers and for studies where the outcomes of interest
were not elevated at baseline (human studies) or in the
control group (animal studies). Due to heterogeneity across
animal studies, meta-regressions for the dose-response of
relative cumulative intake were also performed. Analyses
were performed using R2OpenBUGS (45) and the R wrapper
package brms interfaced with Stan to perform sampling (46).
Certainty assessment
The certainty of each outcome was assessed using the
Grading of Recommendations Assessment, Development,
and Evaluation (GRADE) approach (47), across 5 domains:
risk of bias, inconsistency, indirectness, imprecision, and
publication bias. Outcomes from human trials began with a
high-quality rating, based upon their randomized controlled
trial (RCT) design (as indicated by the eligibility criteria).
This initial rating was subsequently maintained, or down-
graded, based upon performance in each of the 5 domains,
resulting in an overall rating of high, moderate, low, or very
low for each outcome (47). Inconsistency was graded on
visual inspection of effect size estimates, whether credible
intervals overlapped, and between-study variability [τ (tau)];
these factors were considered within the context of the
outcome values at baseline and the cumulative supplement
dose, which could plausibly explain inconsistency (48).
Human studies were not downgraded for indirectness, as
our eligibility criteria narrowly selected for the population,
intervention, and outcomes of interest; further, our primary
outcomes are indirect by nature and used in clinical decision
making. Animal studies were automatically graded down
1 level for indirectness, unless conducted in nonhuman




























n Records identified through electronic
databases (n = 966)
PubMed (n = 80)       CINAHL Complete (n = 19)
Scopus (n = 452)      Web of Science (n = 179)
ProQuest (n = 200)   CENTRAL (n = 36)
Records excluded
(n = 597)
Full-text articles excluded, with 
reasons (n = 39)
Inappropriate population (n = 4)
Inappropriate intervention (n = 4)
Inappropriate comparator (n = 1)
Inappropriate outcome (n = 15)
Inappropriate study design (n = 1)
Multiple inappropriate criteria (n = 4)
Could not obtain data (n = 1)
Duplicate data set (n = 9)
Additional records identified 
through other sources
(n = 4)





Records screened based on title 
and abstract (n = 656) 
Full text articles assessed for 
eligibility (n = 59)
FIGURE 1 PRISMA flow diagram depicting the search and selection process. PRISMA, Preferred Reporting Items for Systematic review
and Meta-Analysis.
primates (49). Imprecision was graded based on the pooled
sample size and the width of the credible intervals: the
interval crossed the null and simultaneously included large
clinical benefit or harm (serious), or the interval included
both a large clinical benefit and harm (very serious) (48, 49).
Publication bias was graded as either detected or undetected
(see “Outcome reporting bias”).
Results
Study selection and characteristics
Figure 1 depicts the search and selection process. Twenty
studies were included in the data synthesis—7 studies in
mice (n = 132 mice), 9 studies in rats (n = 159 rats),
and 4 human studies (n = 172 participants)—providing
data for 2 primary outcomes (fasting glucose and HbA1c)
and 3 additional outcomes [fasting insulin, HOMA-IR,
and homeostatic model assessment for steady-state β-
cell function (HOMA-β)]. As all included animal studies
were conducted in mice or rats, the term rodent(s) is
used herein instead of the nonspecific term animal(s).
Tables 2 and 3 summarize the characteristics of included
human and rodent studies. Human populations included
adults with type 2 diabetes (21, 50), children with type 1
diabetes (51), and nondiabetic adults with overweight or obe-
sity (a subgroup exhibited impaired glucose tolerance) (20).
Rodent disease models included 1) genetic modifications
to develop obesity, hyperglycemia, and insulin resistance
(18, 19, 52, 53); 2) dietary interventions to develop obesity,
hyperglycemia or hyperinsulinemia, and insulin resistance
(54–56); and 3) single or multiple streptozotocin injection(s)
to induce pancreatic β-cell death, leading to hyperglycemia
(57–65).
Data from human studies included between-group pre- to
postintervention changes, whereas rodent studies included
between-group postintervention changes only (e.g., no base-
line data were available), longitudinal repeated measures, and
multiple treatment doses. Only single studies reported 2-h
glucose following a GTT (20), homeostatic model assessment
of insulin sensitivity (HOMA-S) (50), and C-peptide (18),
so these outcomes were not included in the meta-analysis.
We excluded 10 rodent studies that did not record glucose
or insulin in the fasted state, or where the measurement
type was unclear (66–75); some studies also recorded HbA1c,
but this outcome was retained as it does not need to be
recorded in the fasted state (62, 63). Two included studies
were translated from Korean into English (53, 59). The
supplementary information contains individual study data
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used in the analyses (Supplemental Human and Animal
Data); and a list of all excluded full-text studies, including
reasons for exclusion (Supplemental Methods).
Risk of bias assessment
Study risk of bias.
There were no differences in the risk of bias for individual
outcomes within studies, so we allocated a single rating at
the study level. Of the 4 human studies, 1 study showed
some concerns with risk of bias (51), the remaining 3 studies
showed high risk of bias (20, 21, 50) (Supplemental Table
1). This was due to a lack of information on adherence rates
or no adjustment for nonadherence in analyses, which led
to a high risk of bias for domain 2: bias due to deviations
from the intended outcomes. No studies had a prespecified
analyses plan, which led to some concerns for domain 5:
bias in selection of the reported results. The risk of bias
profile, however, was different across studies and 50% of
items showed low risk of bias. Nearly all rodent studies had
the same risk of bias profile: 60% unclear, 38% low, and 2%
high risk of bias (Supplemental Table 2). The majority of
criteria were scored as unclear due to reporting issues, which
is consistent with risk of bias assessments in previous animal
studies (37).
Outcome reporting bias.
Three human studies reported prospective trial registra-
tion [(51), NCT02928250; (21), IRCT2016011211689N2;
(50), ACTRN12613000273785], with a further human study
not reporting trial registration in the manuscript [(20),
NCT02011100]. All outcomes included in this review were
explicitly preregistered in 2 studies (21, 50), whereas the
remaining studies did not preregister HbA1c (51), fasting
glucose (20, 51), fasting insulin, or HOMA-β outcomes (20).
All studies showed internal consistency when comparing the
methods with the reported results.
Small study and publication bias.
Due to the number of available studies, we only assessed
small study bias for fasting glucose and HbA1c in rodent
studies. Visual inspection of funnel plots revealed no
substantive asymmetries, such that we did not conduct a
quantitative assessment (Supplemental Figures 1 and 2).
Results of individual studies
Two human studies did not show any side effects from
carnosine supplementation (20, 51), whereas the remaining
studies did not report information on side effects (21, 50).
Cumulative supplement intake in human studies ranged
from 84 g to 168 g (carnosine) and 112 g (β-alanine), which
translated to estimated relative cumulative intakes of 1.1 g
· kg–1 to 1.7 g · kg–1 [carnosine (20, 21)] and 1.2 g · kg–1
[β-alanine (50)]. It was not possible to estimate the relative
cumulative intake for Elbarbary et al. (51) as body weight
was reported as a standard score. Relative cumulative intakes
in rodent studies ranged from 315 mg · kg–1 to 182 g ·
kg–1 (carnosine) and 52.2 g · kg–1 (β-alanine). There were
FIGURE 2 Bayesian forest plot of meta-analysis for fasting glucose
in human studies. Each interval represents posterior “shrunken”
estimates based on the random-effects model fitting and
borrowing information across studies to reduce uncertainty. Circles
represent the median value along with 90% credible intervals.
Negative values show a reduction in fasting glucose in the
intervention group compared with the control group. This analysis
included 172 human participants (89 intervention/83 placebo).
too few studies for each outcome to reliably explore the
dose-response across human studies. Due to substantial
variability, values from rodent studies were log-
transformed prior to meta-regressions to assess the dose-
response.
Primary outcome: fasting glucose
Human studies.
The meta-analysis model (4 effect sizes from 4 studies)
provided evidence for a decrease in fasting glucose with
supplementation [MD0.5 = –0.95 mmol · L–1 (90% CrI: –2.12
to 0.08); τ 0.5 = 0.97 mmol · L–1 (90% CrI: 0.48 to 2.3)] (Figure
2). A sensitivity analysis, removing data from studies where
participants did not have elevated fasting glucose at baseline
(20), was performed, which provided stronger evidence in
favor of supplementation [MD0.5 = –1.5 mmol · L–1 (90%
CrI: –2.49 to –0.54); τ 0.5 = 0.54 mmol · L–1 (90% CrI: 0.05
to 1.99)]. The probability that the pooled effect size was less
than or equal to the minimal important difference threshold
(≥1 mmol · L–1 reduction) was estimated as P = 0.464
when including all studies and P = 0.841 when restricted
to studies with elevated fasting glucose at baseline (where
P closer to 1 indicates greater certainty based on posterior
inferences).
Rodent studies.
Data from 1 study containing 2 large effect sizes [–20.6
and –20.5 (64)] were deemed outliers and excluded due
to the effect sizes being several-fold higher than all other
studies reporting this outcome. The meta-analysis model (45
effect sizes from 10 studies) provided evidence to support a
decrease in fasting glucose with supplementation [MD0.5 =
–2.26 mmol · L–1 (90% CrI: –4.03 to –0.44); τ 0.5 = 2.7 mmol
· L–1 (90% CrI: 1.6 to 4.7); intraclass correlation coefficient
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(ICC)0.5 = 0.33 (90% CrI: 0.16 to 0.53)] (Figure 3). A
sensitivity analysis was performed removing data from
studies where the method to induce disease did not elevate
fasting glucose (56) and this provided support in favor of
supplementation [MD0.5 = –2.58 mmol · L–1 (90% CrI: –
4.50 to –0.61); τ 0.5 = 2.81 mmol · L–1 (90% CrI: 1.6 to
5.0); ICC0.5 = 0.33 (90% CrI: 0.16 to 0.54)]. The dose-
response analysis with meta-regression of effect size on the
log-transformed cumulative dose showed greater decreases
in fasting glucose with higher doses [β0.5 = –1.7 mmol · L–1
(90% CrI: –2.7 to –0.68); τ 0.5 = 4.1 mmol · L–1 (90% CrI: 2.5
to 6.8)] (Supplemental Figure 3).
Primary outcome: HbA1c
Human studies.
The meta-analysis model (2 effect sizes from 2 studies)
provided evidence for a decrease in HbA1c with supple-
mentation [MD0.5 = –0.91% (90% CrI: –1.46 to –0.39);
τ 0.5 = 0.17% (90% CrI: 0.01 to 1.08)] (Figure 4). The
probability that the pooled effect size was less than or
equal to the minimal important difference threshold (≥0.5%
reduction) was estimated as P = 0.921 (where P closer to 1
indicates greater certainty based on posterior inferences).
Rodent studies.
The meta-analysis model (16 effect sizes from 9 studies)
provided evidence for a decrease in HbA1c with supple-
mentation [random effects model: MD0.5 = –1.05% (90%
CrI: –1.64 to –0.52); τ 0.5 = 0.58% (90% CrI: 0.07 to 1.44);
ICC0.5 = 0.11 (90% CrI: 0.00 to 0.53)] (Figure 5). Initially,
no evidence of a dose response was obtained with meta-
regression of effect size on the log-transformed cumulative
dose [β0.5 = –0.03% (90% CrI: –0.32 to 0.27); τ 0.5 = 0.62%
(90% CrI: 0.08 to 1.52)] (Supplemental Figure 4). However,
1 effect size [cumulative dose: 182 g · kg · bw–1; effect
size: 1.10 (62)] exhibited substantive leverage and removal
of the point within a sensitivity analysis showed a possible
dose-response effect in favor of greater decreases in HbA1c
with higher doses [β0.5 = –0.18% (90% CrI: –0.50 to
0.13); τ 0.5 = 0.57% (90% CrI: 0.08 to 1.39)] (Supplemental
Figure 4).
Additional outcomes: fasting insulin, HOMA-β, and
HOMA-IR
Human studies.
The meta-analysis models provided evidence of a small to
medium effect for a decrease in HOMA-IR [SMD0.5 = –0.41
(90% CrI: –0.82 to –0.07); τ 0.5 = 0.11 (90% CrI: 0.01 to 0.61);
P(≤ –0.2) = 0.853; P(≤ –0.5) = 0.343; P(≤ –0.8) = 0.057]
(Supplemental Figure 5); a small to medium effect in favor
of decreased fasting insulin [SMD0.5 = –0.41 (90% CrI: –0.77
to –0.07); τ 0.5 = 0.10 (90% CrI: 0.01 to 0.52); P(≤ –0.2) =
0.857; P(≤ –0.5) = 0.324; P(≤ –0.8) = 0.041] (Supplemental
Figure 6); and a small effect in favor of decreased HOMA-
β [SMD0.5 = –0.22 (90% CrI: –0.57 to 0.15); τ 0.5 = 0.10
(90% CrI: 0.01 to 0.54); P(≤ –0.2) = 0.532; P(≤ –0.5) =
0.085; P(≤ –0.8) = 0.009] (Supplemental Figure 7) with
supplementation.
Rodent studies.
The meta-analysis models provided some evidence of a
medium effect for decreased HOMA-IR [SMD0.5 = –0.63
(90% CrI: –1.98 to 0.65); τ 0.5 = 0.72 (90% CrI: 0.06 to 2.84);
ICC0.5 = 0.21 (90% CrI: 0.00 to 0.85); P(≤–0.2) = 0.745;
P(≤–0.5) = 0.563; P(≤–0.8) = 0.364] (Supplemental Figure
8) and a small effect in favor of decreased fasting insulin
[SMD0.5 = –0.31 (90% CrI: –1.33 to 0.57); τ 0.5 = 1.03 (90%
CrI: 0.16 to 2.72); ICC0.5 = 0.09 (90% CrI: 0.00 to 0.78);
P(≤ –0.2) = 0.570; P(≤ –0.5) = 0.334; P(≤ –0.8) = 0.177]
(Supplemental Figure 9) with supplementation.
Sensitivity and subgroup analyses
Sensitivity analyses were performed to explore the robustness
of the main analyses against outliers (rodent studies: fasting
glucose and dose-response for HbA1c) and where the
outcomes were not elevated at baseline (rodent studies:
fasting glucose) or in the control group (rodent studies:
fasting glucose). Data for these are presented in the previous
sections. A sensitivity analysis for risk of bias was not
performed due to no human studies being at low risk
of bias and all rodent studies having similar risk of bias
profiles. Only 1 rodent study supplemented with β-alanine,
so meta-regressions for the effect of supplementation type
were not performed. Instead, a sensitivity analysis was
performed to show that the main results were robust to
the removal of the β-alanine data from Stegen et al. (56):
fasting glucose [MD0.5 = –2.36 mmol · L–1 (–4.16 to –
0.49); τ 0.5 = 2.73 mmol · L–1 (1.61 to 4.68); ICC = 0.34
(0.17 to 0.54)], HOMA-IR [SMD0.5 = –0.64 (90% CrI: –
1.82 to 0.47); τ 0.5 = 0.75 (90% CrI: 0.08 to 2.77); P(≤ –
0.2) = 0.793; P(≤ –0.5) = 0.608; P(≤ –0.8) = 0.383], and
fasting insulin [SMD0.5 = –0.33 (90% CrI: –1.50 to 0.57);
τ 0.5 = 1.07 (90% CrI: 0.15 to 2.80); ICC0.5 = 0.15 (90% CrI:
0.00 to 0.82); P(≤ –0.2) = 0.597; P(≤ –0.5) = 0.375; P(≤ –
0.8) = 0.213]. Because there were no substantive differences,
data from both supplementation groups in Stegen et al.
(56) were combined into a single pooled effect size for the
study.
Certainty of evidence
There was moderate certainty in the effect estimates for
human study outcomes. All outcomes were downgraded 1
level due to concerns with imprecision and risk of bias. It
was decided not to rate down an additional level for the
other outcomes, as there were no concerns with publication
bias or inconsistency. There was very low certainty in the
effect estimates for rodent study outcomes. All outcomes
were downgraded 1 level, due to the prespecified criteria for
indirectness and an additional level due to serious concerns
with risk of bias and serious or very serious concerns with
imprecision. The summary of findings table depicts the
full GRADE assessment, with footnotes explaining each
judgment (Supplemental Table 3).
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FIGURE 3 Bayesian forest plot of meta-analysis for fasting glucose in rodent studies. Each interval represents posterior “shrunken”
estimates based on the random-effects model fitting and borrowing information across studies to reduce uncertainty. Circles represent
the median value along with 90% credible intervals. Negative values show a reduction in fasting glucose in the intervention group
compared with the control group. This analysis included 229 rodents (111 intervention/118 control).
Discussion
Summary of main findings
We included all available human and animal data to provide
the most comprehensive assessment to date of the effects
of carnosine and β-alanine supplementation on glycemic
control and insulin resistance. Our main findings show
FIGURE 4 Bayesian forest plot of meta-analysis for HbA1c in
human studies. Each interval represents posterior “shrunken”
estimates based on the random-effects model fitting and
borrowing information across studies to reduce uncertainty. Circles
represent the median value along with 90% credible intervals.
Negative values show a reduction in HbA1c in the intervention
group compared with the control group. This analysis included 134
human participants (67 intervention/67 placebo). Both studies
supplemented with carnosine. HbA1c (HbA1c), glycated
hemoglobin.
that supplementation improves glycemic control across a
range of disease types in humans (type 1 diabetic children,
type 2 diabetic adults) and rodents (genetic models of
obesity and diabetes, diet-induced metabolic syndrome, and
pharmacological models of type 1 diabetes). As would be
expected, there was no improvement in fasting glucose in
normoglycemic populations. Of clinical relevance is the
high probability that supplementation improves impaired
fasting glucose (P = 0.841) and HbA1c (P = 0.921) beyond
the minimal important difference thresholds (≥1 mmol
· L–1 and ≥0.5% reduction). Data from animal studies
support these findings, which strengthens our confidence
in the effect. We also show evidence of a possible dose-
response effect in animals, in favor of higher cumulative
intakes causing greater reductions in fasting glucose and,
possibly, HbA1c. The positive effects are driven primarily
by carnosine supplementation, as only 1 human and 1
animal study supplemented with β-alanine (50, 56). There
were insufficient data to assess the effect of supplementation
on our other prespecified primary outcome: 2-h glucose
following a GTT. Additional results show evidence of a
small to medium effect in favor of supplementation reducing
fasting insulin and HOMA-IR in humans. While there was
some evidence in favor of supplementation reducing HOMA-
β in humans, and fasting insulin and HOMA-IR in animals,
it was not possible to rule out a neutral or negative effect for
these outcomes.
Proposed mechanisms
The inconsistent effects for fasting insulin across ani-
mal studies could be due to the relationship between
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FIGURE 5 Bayesian forest plot of meta-analysis for HbA1c in rodent studies. Each interval represents posterior “shrunken” estimates
based on the random-effects model fitting and borrowing information across studies to reduce uncertainty. Circles represent the median
value along with 90% credible intervals. Negative values show a reduction in HbA1c in the intervention group compared with the control
group. This analysis included 260 rodents (127 intervention/133 control). All studies supplemented with carnosine. HbA1c (HbA1c),
glycated hemoglobin.
hyperinsulinemia and insulin resistance, where an improve-
ment in one may, paradoxically, lead to a decline in the other
[for a commentary, see (76)]. Two long-term studies showed
that supplementation attenuated the development of hyper-
glycemia in genetically modified mice (18, 19). Both studies
reported an increase in fasting insulin, and 1 reported a 2-fold
increase in C-peptide—a specific marker of insulin secretion
(18). This suggests that carnosine might enhance insulin
secretion from pancreatic β-cells, which may compensate for
peripheral insulin resistance, leading to an improvement in
glycemic control. Further, as supplementation began prior to
disease development, it is possible that carnosine can play
a role in preventing or delaying disease progression. One
human study supports this: a subgroup of participants with
impaired glucose tolerance displayed normal 2-h glucose
and reduced 2-h insulin following supplementation (20).
This suggests that carnosine might also improve postprandial
glucose disposal, potentially by reducing peripheral insulin
resistance. Consistent with these hypotheses, work from
our research group showed that treatment with carnosine
reverses glucolipotoxic inhibition of insulin secretion in
isolated mouse islets and INS-1 pancreatic β-cells, as well as
insulin-stimulated glucose uptake in C2C12 skeletal muscle
cells (12). Together, this suggests that carnosine might exert
beneficial effects in multiple tissues.
Improvements in glycemic control can protect organs and
tissues from complications associated with diabetes. In type
1 diabetic children, Elbarbary et al. (51) showed a large
decrease in plasma ɑ1-microglobulin (–44%) and the urinary
albumin to creatinine ratio (UACR; –58%), which suggests
that carnosine might have a protective effect on kidney
function and may lower the risk of diabetic nephropathy.
In support, several rodent studies showed reductions in
the UACR (18, 52, 60, 61), as well as reductions in blood
urea nitrogen and serum creatinine (60). Interestingly, these
improvements occurred in 2 studies without a change in
fasting glucose (52, 60). The studies showed an 11-fold and
4-fold increase in kidney carnosine concentrations following
supplementation, supporting prior research that the human
kidney has an intrinsic system for metabolizing carnosine (8).
It is possible that some of the beneficial effects of carnosine
occur directly in the kidney and may be independent of its
actions on glycemic control—with positive outcomes in both
type 1 and type 2 diabetes.
The most plausible mechanism by which carnosine
provides a therapeutic effect is through its ability to form
stable adducts with reactive carbonyl species, such as
acrolein, 4-hydroxynoneal, and methylglyoxal (13, 77). These
toxic products increase with diabetes severity and cause
deleterious modifications to proteins, lipids, and DNA—
inducing inflammation and insulin resistance, and impairing
insulin secretion (12, 78–80). By scavenging these products,
carnosine reduces their reactivity, allowing them to be safely
metabolized or excreted from the body (14, 81, 82), which
limits downstream formation of advanced glycation and
advanced lipid-oxidation end products (AGEs and ALEs).
Indeed, human and rodent studies showed supplementation
protected against oxidative stress, lipid peroxidation, AGEs,
and ALEs (18, 21, 51, 52, 55–57, 60, 62, 63, 65). It is also
possible that carnosine works indirectly by activating the
nuclear factor erythroid 2-related factor 2 (Nrf2) signaling
cascade, which enhances endogenous antioxidant and anti-
carbonylation defense systems [for a detailed review, see
(83)].
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There is a debate over the location of these actions.
Some studies suggest that carnosine can act on reactive
species and inflammatory markers in plasma, meaning that
raising plasma carnosine would be key to any potential
therapeutic effects (56). Although this might be true for
rodents, where low carnosinase activity means that carnosine
readily circulates in plasma and fasted values can increase
25-fold with supplementation (56), it seems unlikely to be as
important in humans given that carnosinase is highly active
in enterocytes and plasma, rapidly hydrolyzing carnosine
(84, 85). As such, plasma carnosine concentrations remain
below the limit of detection (11, 86). In a subgroup of
individuals with low plasma carnosinase activity, a single
dose of carnosine (60 mg · kg–1; 4.2 g for a 70-kg individual)
increased plasma carnosine concentrations to a peak of 73.3
μM, before returning to baseline within 1–2 h (87).
Carnosine might instead act in human tissues that syn-
thesize it in situ—those expressing carnosine synthase and
transporters for β-alanine and histidine—and which play
an important role in the pathogenesis of insulin resistance
and diabetes. Recent genetic studies support the tissue–
carnosine hypothesis: overexpression of cardio-specific ATP-
grasp domain-containing protein 1 (ATPGD1; carnosine
synthase) increased carnosine and anserine concentrations
in the myocardium of mice, which reduced protein-aldehyde
adducts and gave protection against ischemia reperfusion in-
jury (88), whereas knockout of glutamic acid decarboxylase–
like 1 (GADL1) reduced carnosine concentrations in the
olfactory bulb and skeletal muscle, leading to increased
markers of oxidative stress (89). Based on this evidence,
increasing tissue carnosine stores should be the primary goal
of supplementation. The included human studies, however,
used a dose or duration that would cause only a modest
increase in tissue carnosine stores (90, 91). de Courten et
al. (20) was the only human study to quantify the change
in tissue carnosine, reporting a 33% increase in skeletal
muscle stores after supplementing with 2 g · d–1 carnosine
for 12 wk. In contrast, nonclinical studies often supplement
with 3.2 g · d–1 to 6.4 g · d–1 of β-alanine, whereby large
cumulative intakes (24 wk; 1075.2 g total) can lead to a 2-
fold increase in skeletal muscle carnosine content (92). It is
worth noting that Nealon et al. (50) used a high β-alanine
dose and showed improvements in glycemic control and
insulin resistance in a 4-wk period. The comparably low
relative cumulative intakes in human studies, coupled with
the evidence of a dose-response in rodent studies, suggest
that there could be room for further improvement in human
outcomes. Future studies should consider the type, dose, and
duration of supplementation.
While our study provides evidence in favor of supplemen-
tation, we recommend caution as the results require repli-
cation in large-sample, high-quality studies. The GRADE
assessment showed our certainty in the effect estimates
from human studies is moderate, which suggests the true
effect is likely to be close to the estimate of the effect, but
there is a possibility that it is substantially different (48).
Further, the certainty in all outcomes from rodent studies was
graded as very low, due to inconsistency, imprecision, and
indirectness. Despite this, results from animal and human
studies agree, which collectively adds weight to the main
findings and shows that changes in rodent outcomes for
glycemic control and insulin resistance may translate to
humans. Given the inherent limitations in preclinical studies,
however, caution is needed when interpreting the rodent
outcomes for the purposes of choosing treatment options for
humans.
Limitations in the research
Our study highlights several limitations in the existing
evidence base, which future studies can improve upon. No
human studies were at a low risk of bias. To address this,
researchers should provide clear information on random-
ization and allocation concealment, publish a prespecified
statistical analysis plan within the trial registration, and
rigorously assess and report adherence and blinding to the
intervention. All human studies were of short duration (≤3
mo) with modest cumulative intakes; it is possible that
longer-duration studies with higher cumulative intakes could
lead to better clinical outcomes, consistent with the dose-
response results in rodents. This is particularly important
since diabetic complications develop over many years and
may not be captured in short-duration studies. Several rodent
studies did not contain the relevant information to assess the
risk of bias; researchers should aim to satisfy the SYRCLE
criteria and follow animal study reporting guidelines [e.g.,
the ARRIVE guidelines (93)]. Preclinical researchers should
also design studies that translate to human clinical outcomes;
several rodent studies were excluded from the current
analysis because they did not record glucose or insulin in the
fasted state. While certain disease models cannot be fasted
for prolonged periods due to ethical concerns, it is often
possible to conduct a short-term fast during the light phase
in rodents that is equivalent to an overnight fast in humans
(94). Our study focused upon surrogate outcomes involved
in diabetes diagnosis and clinical decision making. These
are important, although future RCTs should collect data on
key patient-centered outcomes, such as disease progression
rates, diabetic symptoms, hospital admissions, and diabetic
complications.
Conclusions
Our study provides evidence that supplementation with
carnosine or β-alanine may reduce fasting glucose, HbA1c,
and HOMA-IR in humans and rodents, and fasting insulin
in humans. There is a need, however, for longer-term studies
(>3 mo), in large samples, using dynamic methods to
assess glycemic control and insulin resistance (e.g., GTTs
and glucose clamp techniques). To improve the certainty
in future findings, researchers should also explore dose-
response effects in humans, whether treatment effects are the
same for carnosine and β-alanine, and address shortcomings
in study designs and reporting. Despite these caveats, our
promising results indicate that carnosine and β-alanine
supplementation remain viable therapeutics to improve
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glycemic control and insulin resistance in diabetes and its
related conditions. The results of the current study provide
a foundation upon which ongoing studies can be based,
with the goal of defining whether this strategy is suitable for
widespread population-level implementation.
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